Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report
Yonsei Medical Journal · 2026 · 67
DOI: 10.3349/ymj.2026.0203 ↗Kurz gefasst
Fallbericht in der Zeitschrift Yonsei Medical Journal, 2026. Verfasst von Shi Hyun Kim und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kim, S. H., Jain, S., Shim, J. S., Cho, B. C., & Lim, S. M. (2026). Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report. Yonsei Medical Journal, 67. https://doi.org/10.3349/ymj.2026.0203
Vancouver
Kim SH, Jain S, Shim JS, Cho BC, Lim SM. Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report. Yonsei Medical Journal. 2026;67. doi:10.3349/ymj.2026.0203
BibTeX
@article{Kim2026,
author = {Kim, Shi Hyun and Jain, Suyog and Shim, Joo Sung and Cho, Byoung Chul and Lim, Sun Min},
title = {Response to Zongertinib in EGFR -Mutant NSCLC with Acquired HER2 Amplification after Lazertinib and Amivantamab: A Case Report},
journal = {Yonsei Medical Journal},
year = {2026},
volume = {67},
doi = {10.3349/ymj.2026.0203}
}
EUVIMED